Long-Acting Injectable Tracker

Platforms

Assets

Approved

Deals

166

Trials

108

IP records

Companies

Platform × Indication Fit

Hover any cell for the scoring rationale.

Platform	Psych	Addiction	HIV	Oncology	Endocrine	Ophtho	Pain	Metabolic
Atrigel	2·	5	—	5	3·	—	—	—
BEPO	5	3·	3·	3·	—	4·	—	—
Biochronomer	—	—	—	3·	—	—	4	—
Chroniject	—	—	—	—	—	—	—	—
DepoFoam	—	—	—	1	—	—	4	—
Durasert	—	—	—	—	—	5	—	—
FluidCrystal	3·	5	—	3·	4	—	—	5
ISM	4	—	—	3·	3·	—	—	—
Lupron Depot	—	—	—	5	5	—	—	—
MariTide platform (Amgen)	—	—	—	—	—	—	—	4·
Medisorb	5	4	—	—	3·	—	—	—
Medusa	—	—	—	—	—	—	—	3·
Metsera depot platform	—	—	—	—	—	—	—	4·
NanoCrystal	5	—	5	—	—	—	—	—
NanoZolid	—	—	—	3·	—	—	—	—
Novadur	—	—	—	—	—	5	—	—
Oil decanoate	4	—	—	4	5	—	—	—
PDS (Susvimo)	—	—	—	—	—	5	—	—
Perseris	3	—	—	—	—	—	—	—
PolyActiva	—	—	—	—	—	3·	—	—
Probuphine	—	2	—	—	—	—	—	—
Sandostatin LAR	—	—	—	4	5	—	—	—
Signifor LAR	—	—	—	3·	4	—	—	—
Somatuline Autogel	—	—	—	5	5	—	—	—
SpectruM	—	—	—	4	—	—	—	—
Trelstar	—	—	—	5	4	—	—	—
Zoladex	—	—	—	5	4	—	—	—
iDose	—	—	—	—	—	5	—	—

5 best-in-class 4 above avg 3 neutral 2 below avg 1 weak Confidence: full opacity = high; · medium; ? low

Platform composite scores

Weighted: tech 40% · IP 30% · dealability 30%. Hover any bar segment for the rationale; click a row to expand full detail.

Atrigel

3.15

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	5	high	Longest commercial track record of any in-situ depot LAI platform; two decades of manufacturing refinement; broad payload experience across small molecules and peptides.	RX · 2026-04-21
ip	2	high	Core patents expired; generic competition to Eligard emerging; platform-level exclusivity now depends on manufacturing trade secrets rather than composition-of-matter.	RX · 2026-04-21
dealability	3	medium	Historical partnering track record (AstraZeneca, Sanofi, Astellas, Indivior) demonstrates dealability, but IP expiry limits incremental licensing value; current positioning more manufacturing-services than platform licensor.	RX · 2026-04-21
availability	2	medium	Tolmar (private) commercializes Eligard directly and supplies Sublocade to Indivior under contract; no active platform-licensing posture for external partners. Atrigel core composition IP expired 2008 — manufacturing know-how is the residual moat. Available scope is narrow.	CL · 2026-04-27

Analytical view
Platform value has shifted from IP-protected technology to manufacturing and regulatory moat. Still commercially important via Eligard and Sublocade but low investability as a standalone platform story. Reference point for what happens to in-situ depot platforms after core IP expires.

BEPO

3.75

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	UZEDY commercial approval + olanzapine NDA under review validate the platform; payload breadth demonstrated to peptides in preclinical but not yet clinically.	RX · 2026-04-21
ip	4	medium	Core patents to 2031 with active continuation strategy through 2038+; AbbVie FTO diligence suggests no material exposure.	CL · 2026-04-26
dealability	5	high	Two tier-1 pharma partnerships (Teva, AbbVie), six-program AbbVie expansion plus option structures, mid-to-high single-digit royalties reference market-plus.	RX · 2026-04-21
availability	2	medium	Most indications encumbered — psych locked under Teva, plus AbbVie locks oncology/ophthalmology/cns_neuro/"other". Open scope effectively limited to addiction (commercially crowded), HIV, non-incretin metabolic, pain. Posture is selective but available scope is narrow.	CL · 2026-04-26

Analytical view
Best-positioned non-microsphere in-situ depot platform but overpriced before olanzapine PDUFA resolves. Teva concentration risk is the central tension.

Biochronomer

2.75

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	high	Two approved products demonstrate platform viability but both in short-duration applications; mechanism limited beyond 7-day depots.	CL · 2026-04-25
ip	3	medium	Reasonable continuation strategy; novel polyorthoester mechanism distinguishes IP space from PLGA-class platforms.	CL · 2026-04-25
dealability	2	medium	Heron commercializes both products internally; no major external licensing precedent for the platform.	CL · 2026-04-25
availability	3	medium	Heron commercializes Zynrelef and Sustol directly using Biochronomer; platform-licensing posture is selective given cash-runway pressure. Plausibly available for non-pain / non-CINV indications subject to Heron's strategic focus.	CL · 2026-04-27

Analytical view
Specialty short-duration depot platform with two approved products in two distinct therapeutic areas. Limited platform-licensing optionality given Heron's internal commercialization strategy and short-duration mechanism profile. Monitor Zynrelef commercial trajectory as a leading indicator for postsurgical-pain LAI category economics.

Chroniject

3.30

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	medium	25+ years platform history but no Chroniject-branded approved products; partnered programs in clinical development. Capability evidenced but commercial validation pending.	CL · 2026-04-25
ip	2	medium	PLGA microsphere mechanism is generic; platform value resides in manufacturing scale and CDMO services rather than IP-protected technology.	CL · 2026-04-25
dealability	3	medium	CDMO model means dealability is structurally limited to development-services revenue rather than royalty-bearing licenses; partner-program approach generates recurring engagement but smaller economics per deal.	CL · 2026-04-25
availability	5	high	Oakwood Laboratories' core business model is partner-funded reformulation programs on Chroniject — the platform is structurally open to any pharma seeking microsphere LAI development. CDMO fee-for-service plus royalty structure standard.	CL · 2026-04-27

Analytical view
Capacity provider rather than investable platform. Strategic relevance is primarily as a window into the broader LAI development pipeline — Oakwood's partner roster (when disclosed) reveals which biotechs are pursuing microsphere reformulations. Not a primary investment target on its own merits.

DepoFoam

2.05

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	high	One commercially significant product (Exparel) but two prior products withdrawn; mechanism niche to local-site short-duration applications rather than systemic LAI.	CL · 2026-04-25
ip	2	medium	Core platform IP expired; ongoing litigation indicates exposure rather than strength; generic competition imminent or active.	CL · 2026-04-25
dealability	2	medium	Pacira's commercialization is internal; no external platform licensing precedent of note; product-focused company strategy.	CL · 2026-04-25
availability	1	high	Pacira BioSciences-internal asset for Exparel; mechanism niche to local administration limits transferability. No platform-licensing posture for external partners. Closed.	CL · 2026-04-27

Analytical view
Niche local-administration liposomal depot with limited transferability beyond regional anesthesia. Strategic relevance to broader LAI thesis is primarily as a counterexample — demonstrates that not all "depot" platforms generalize across indications. Pacira's investment thesis is product-specific, not platform-driven.

Durasert

3.80

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	5	high	Four approved products spanning 25+ years; demonstrated up to 36-month durations; only commercial LAI platform achieving multi-year sustained ophthalmic delivery.	CL · 2026-04-25
ip	4	medium	Layered platform and product IP plus next-generation bioerodible variant in development; meaningful runway though specific expiry years require verification.	CL · 2026-04-25
dealability	3	medium	Alimera partnership for Iluvien is the largest external commercial expression; recent EyePoint strategy more internally focused on EYP-1901 development.	CL · 2026-04-25
availability	3	medium	EyePoint actively partners Durasert: Alimera (Iluvien, since 2008), Astellas (2023 retinal TKI collaboration), Ono (2024 Asia EYP-1901 rights). Demonstrated openness to external partners in ophthalmic scope, though core wet-AMD economics retained internally.	CL · 2026-04-27

Analytical view
The reference platform for ophthalmic implant LAI. Strategic question is whether EyePoint's pipeline — particularly EYP-1901 in wet AMD — can establish a sustained-release alternative to monthly anti-VEGF injections. If successful, the platform could redefine retinal disease economics; if not, Durasert remains a niche steroid-implant business.

FluidCrystal

4.10

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	5	high	Two approved products in two regions (Buvidal EU, Brixadi US), demonstrated payload breadth including peptides (CAM2029 octreotide Phase 3), duration range from weekly to six-monthly is widest in category.	RX · 2026-04-21
ip	3	medium	Core platform patents approaching 2030 expiry; continuation strategy moderate but earlier filings mean less runway than BEPO or Atrigel newer filings.	RX · 2026-04-21
dealability	5	high	June 2025 Eli Lilly $870M cardiometabolic incretins deal (up to four GIP/GLP-1 compounds, mid-single-digit royalties) validates FluidCrystal at tier-1 pharma counterparty level. Combined with Buvidal direct commercialization (~SEK 1.65B / USD 157M FY2024 product sales) and Brixadi US royalties (SEK 212M FY2024), Camurus now demonstrates both internal commercialization scale AND tier-1 external licensing optionality.	CL · 2026-04-25
availability	3	medium	Addiction and metabolic/endocrine encumbered by Braeburn and Lilly respectively, but oncology, ophthalmology, CNS-neuro, and pain are open. Selective posture and engaged BD function support an "open in some TAs" read.	CL · 2026-04-26

Analytical view
Re-rated platform post-June 2025 Eli Lilly $870M deal. FluidCrystal is now the only LAI platform with both meaningful direct-commercial scale AND tier-1 pharma external licensing.

ISM

3.50

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	One approved product in two major regions; novel mechanism distinct from competing in-situ depots; second-generation candidates (letrozole, others) in development.	CL · 2026-04-25
ip	4	medium	Newer filings than Atrigel/FluidCrystal provide longer runway; continuation strategy active.	CL · 2026-04-25
dealability	3	medium	Rovi commercializes Okedi/Risvan directly in EU; no major external platform licensing announced; commercialization-heavy strategy reduces deal datapoints.	CL · 2026-04-25
availability	3	medium	Rovi (founder-controlled mid-cap) retains EU commercialization for Risvan but has historically explored US/ROW out-licensing for the platform. Available scope outside EU psych is plausible; founder-family voting structure complicates platform-level deals.	CL · 2026-04-27

Analytical view
European challenger platform with single-product commercialization in psych. Strategic question: can Rovi differentiate from BEPO-derived UZEDY or Risperdal Consta on duration, tolerability, or pricing? Without a clear edge, ISM risks becoming the fourth-place risperidone LAI rather than a platform commanding licensing premium.

Lupron Depot

2.20

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	5	high	Multiple duration formats over 35+ years; foundational peptide LAI; manufacturing at industrial scale long-established.	CL · 2026-04-25
ip	1	high	Off-patent; competing generic and innovator products active.	CL · 2026-04-25
dealability	1	high	Not a licensable external platform; product-specific manufacturing.	CL · 2026-04-25
availability	1	high	AbbVie/Takeda-internal mature franchise; no platform-licensing posture. Closed.	CL · 2026-04-27

Analytical view
Tracked as competitive context — Lupron Depot is the price/share anchor for prostate cancer LHRH LAI globally. Any new entrant must position against Lupron's prescriber inertia and Takeda/AbbVie commercial scale. Strategic relevance is in deal pricing — historical Lupron economics inform what new LHRH LAI entrants can realistically command.

MariTide platform (Amgen)

2.20

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	medium	Phase 2 data positive; Phase 3 program initiated 2024-2025; technical category is half-life extension, not depot LAI per se.	CL · 2026-04-26
ip	4	medium	US10905772B2 (priority Jan 2017, expiry 2038) granted method-of-treatment claims for GIPR-antagonist + GLP-1 conjugates; international counterpart WO2018237095A1. Active continuation strategy via WO2024102742A1 (priority Nov 2022) extends methods-for-obesity claims; national-stage filings in EP/JP/CN/KR/IL/PE/MX/JO/CO. No public oppositions or PTAB challenges identified.	CL · 2026-04-27
dealability	1	high	Internal Amgen asset; not externally licensable.	CL · 2026-04-26
availability	1	high	Fully internal — not available to third parties.	CL · 2026-04-26

Analytical view
Competitive context for FluidCrystal incretin program. MariTide is half-life extension rather than depot LAI but competes for the same obesity-LAI market.

Medisorb

3.40

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	5	high	Three approved products spanning small molecules and peptides over two decades; foundational microsphere platform with robust commercial track record.	CL · 2026-04-25
ip	2	medium	Core composition-of-matter expired; platform exclusivity now dependent on manufacturing trade secrets and product-specific patents.	CL · 2026-04-25
dealability	4	medium	Historical partnerships with Janssen and AstraZeneca demonstrate dealability; current Alkermes strategy more product-focused than platform-licensing.	CL · 2026-04-25
availability	2	medium	Alkermes had an open NanoCrystal/Medisorb licensing posture in the 1990s-2010s (Janssen, AstraZeneca/Lilly). Current focus is internal pipeline and existing royalty streams; no signal of active external partnering for new programs. Bydureon endocrine encumbrance limits incretin scope.	CL · 2026-04-27

Analytical view
Foundational microsphere platform whose strategic relevance has shifted from technology innovation to manufacturing scale. Alkermes' product portfolio built on Medisorb generates substantial revenue, but the platform itself is no longer a credible licensing story. Reference point for what mature LAI technology looks like post-IP cliff.

Medusa

2.70

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	2	high	No approved products; multiple Phase 1-2 programs but no Phase 3 readouts; mechanism interesting but commercial validation pending.	CL · 2026-04-25
ip	3	medium	Reasonable patent runway with continuation activity.	CL · 2026-04-25
dealability	2	medium	Adocia has had partnership terminations historically (Eli Lilly BioChaperone Lispro program ended); demonstrated dealability but with execution risk visible to counterparties.	CL · 2026-04-25
availability	4	medium	Adocia's commercial model is platform-licensing-driven (BioChaperone). After the 2017 Lilly partnership termination, Adocia has actively signaled openness to new partnerships; small-cap with cash-runway pressure increases willingness to deal. Track record warning: execution risk on partner programs.	CL · 2026-04-27

Analytical view
French formulation platform with chronic execution challenges. Strategic relevance is primarily as a counterexample for dealability — the 2017 Lilly partnership termination on BioChaperone Lispro illustrates how formulation-platform companies can lose tier-1 relationships when underlying programs disappoint. Tracking value low unless a specific program reaches Phase 3.

Metsera depot platform

3.20

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	medium	VESPER-1 Phase 2b (Sept 2025) confirmed HALO peptide-lipidation platform translates ultra-long PK (15-16 day half-life) into clinical weight loss — late-clinical platform validation. Multiple programs (MET-097, MET-233, MET-067) under same platform across GLP-1/amylin/GIP. Not yet commercial; Pfizer-led Phase 3 starting late 2025.	CL · 2026-04-27
ip	4	medium	WO2017178829A1 (priority April 2016, expiry ~2037) provides foundational composition-of-matter coverage of peptide hormone analogues (Exendin-4, GLP-1, OXM, glucagon variants) — in-licensed to Zihipp/Metsera from Imperial College / IP2IPO. Underlying library of 20,000 peptides supports MET-097, MET-233, MET-034, MET-067. Pfizer post-acquisition adds tier-1 patent infrastructure plus continuation strategy. Royalty obligations to IP Group plc are a secondary economic consideration but do not weaken the freedom-to-operate position.	CL · 2026-04-27
dealability	5	medium	Pfizer 2025 acquisition validates platform commercial value at tier-1 level.	CL · 2026-04-26
availability	1	high	Acquired by Pfizer; not externally available.	CL · 2026-04-26

Analytical view
Pfizer-acquired competitor in obesity-LAI. Tracked for competitive context.

NanoCrystal

3.35

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	5	high	Multiple commercial successes across psych and HIV; demonstrated 6-month duration capability (Invega Hafyera, longest LAI antipsychotic); platform validated for low-solubility small molecules.	CL · 2026-04-25
ip	3	medium	Platform IP largely expired; product-level patents preserve commercial exclusivity for individual drugs but not for new entrants using the mechanism.	CL · 2026-04-25
dealability	3	medium	Two tier-1 commercial relationships (Janssen, ViiV) but Alkermes does not actively license the platform externally; deal optionality is largely captured.	CL · 2026-04-25
availability	2	medium	Alkermes-derived NanoCrystal IP estate is now Janssen-controlled for the active Invega and cabotegravir LAI franchises. ViiV/Janssen HIV scope is encumbered; Janssen psych scope is internal-only. Limited available scope absent specific Janssen out-licensing — none signaled.	CL · 2026-04-27

Analytical view
Most commercially successful LAI platform by revenue, with Invega franchise and cabotegravir generating multi-billion-dollar combined sales. Strategic value resides in existing product franchises rather than platform licensing potential. Watch Janssen's response as Invega Sustenna faces generic LOE beyond 2030 — Hafyera's 6-monthly duration is the franchise's defensive moat.

NanoZolid

3.00

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	medium	No approved products; broad payload claims (small molecules through proteins) but only one clinical candidate at Phase IIb; biologic capability mostly preclinical.	CL · 2026-04-25
ip	3	medium	Reasonable runway with continuation activity; novel inorganic-matrix mechanism distinguishes IP from polymer-platform competitors.	CL · 2026-04-25
dealability	2	medium	No major partnerships announced; small-cap European biotech with limited tier-1 outreach evident.	CL · 2026-04-25
availability	4	medium	LIDDS (Swedish micro-cap) actively shops NanoZolid for partnership; platform IP available across multiple oncology and intra-articular scopes. Cash-runway pressure increases willingness. Phase IIb data confirmation needed before tier-1 partnership likely materializes.	CL · 2026-04-27

Analytical view
Speculative early-stage platform with single Phase IIb asset. Strategic interest is twofold — (1) the active-surveillance prostate cancer niche is under-served and could support a niche commercial product; (2) the inorganic-matrix mechanism is genuinely differentiated from polymer depots and may prove more compatible with sensitive payloads. Both theses require Phase IIb data confirmation before becoming actionable.

Novadur

2.55

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	Two approved ophthalmic products across distinct administration routes (intravitreal, intracameral); 3-6 month duration well-characterized; bioerodible mechanism eliminates implant removal step.	CL · 2026-04-25
ip	3	medium	Mid-stage IP runway with continuation activity; some generic pressure on Ozurdex. Confidence medium pending Orange Book check.	CL · 2026-04-25
dealability	2	medium	AbbVie commercializes both products internally; no external licensing precedent for the platform.	CL · 2026-04-25
availability	1	high	AbbVie/Allergan-internal; supports Durysta commercial product. No platform-licensing posture for external partners. Closed.	CL · 2026-04-27

Analytical view
AbbVie-owned ophthalmic implant platform paralleling Durasert in indication but distinguished by bioerodibility. Strategic interest is comparative — Novadur vs Durasert for a given drug class informs whether reformulation candidates favor erodible (3-6 month) or non-erodible (12-36 month) variants. The recent BEPO-AbbVie deal may also intersect this space as AbbVie's broader LAI strategy evolves.

Oil decanoate

3.20

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	5	high	Decades of clinical and commercial use; reliable PK well-characterized for esterifiable molecules; longest commercial track record of any LAI platform category.	CL · 2026-04-25
ip	1	high	Off-patent generic chemistry; no exclusivity to be captured.	CL · 2026-04-25
dealability	1	high	Not a proprietary platform; no licensing opportunity.	CL · 2026-04-25
availability	5	high	Off-patent generic vehicle technology; freely available to any manufacturer worldwide. No platform-level encumbrance possible. Multiple commercial decanoate antipsychotics globally.	CL · 2026-04-27

Analytical view
Tracked for competitive context, not investability. Oil decanoate solutions are the price-anchor floor for LAI markets — any newer platform must justify premium pricing relative to this generic baseline. The continued commercial life of decanoate antipsychotics in cost-sensitive markets is a structural headwind for innovator LAI economics outside high-income geographies.

PDS (Susvimo)

2.50

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	First commercial LAI for ophthalmic biologic delivery; achieves 6-month dosing for ranibizumab where conventional intravitreal injections require monthly. Recall history modestly weakens the score.	CL · 2026-04-25
ip	4	medium	Device-based platform with proprietary IP; novel category with limited direct competition.	CL · 2026-04-25
dealability	1	high	Roche-developed and commercialized; not a licensing platform; closed strategic asset.	CL · 2026-04-25
availability	1	high	Roche/Genentech-internal device technology supporting Susvimo. No platform-licensing posture. Closed.	CL · 2026-04-27

Analytical view
Not investable directly (Roche-internal) but strategically critical reference for any retinal-disease LAI thesis. PDS effectively defines the upper bound of what biologic LAI can achieve commercially. The recall and relaunch arc is also a cautionary case study for device-formulation hybrid approaches.

Perseris

2.25

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	high	One approved product; mechanism similar to Atrigel and Sublocade-class PLGA in-situ depots; not platform-defining.	CL · 2026-04-25
ip	3	medium	Product-specific patents provide commercial moat; platform mechanism IP largely shared with broader PLGA in-situ category.	CL · 2026-04-25
dealability	2	high	Recent divestiture from Indivior to Newron signals limited strategic priority; platform-level dealability marginal.	CL · 2026-04-25
availability	1	medium	Indivior discontinued Perseris in July 2024. Platform basis is Atrigel-derived; no separate external availability outside the broader Atrigel platform. Effectively closed.	CL · 2026-04-27

Analytical view
Marginal platform tracked for completeness in risperidone LAI competitive set. Indivior's divestiture to Newron suggests the asset is non-core for its original developer; commercial trajectory uncertain. Limited investment thesis on its own.

PolyActiva

3.25

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	medium	Clinical-stage only; no approved products; mechanism within established polymer-implant category but specifics differentiated by claimed 6-month duration.	CL · 2026-04-25
ip	3	medium	Composition-of-matter patent estate for biodegradable polymer-rod intracameral implant filed mid-2010s; effective protection through ~2035-2040 base. Private filing with limited public visibility, but company has stated FTO position is clear. Specific patent search would refine; estate is real but not exhaustively reviewed.	CL · 2026-04-27
dealability	3	medium	Active partnership discussions disclosed by company since 2023 (no executed exclusive deal) signal genuine BD activity. Reference comp: Glaukos iDose-licensed precedents and AbbVie/Allergan Durysta establish that ophthalmic implant LAI commands tier-1 economics post-Phase-3 readout. Pre-pivotal so dealability is theoretical.	CL · 2026-04-27
availability	4	medium	PolyActiva (private AU) has signaled active partnering discussions around PA5108 Phase 3 readiness through 2024-2025 (no executed exclusive deal disclosed). Platform structure is partnership-dependent given the company's clinical-stage scale.	CL · 2026-04-27

Analytical view
Speculative emerging-platform watchlist entry. PolyActiva represents the next-generation challenger thesis to Durysta in glaucoma — if Phase 3 data supports superior duration with comparable safety, the platform could attract Big Pharma interest. Pre-clinical-readout, pure optionality.

Probuphine

1.60

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	high	Approved product but commercial uptake limited; required surgical insertion/removal added friction vs. injectable LAI competitors (Sublocade, Brixadi); platform stalled commercially.	CL · 2026-04-25
ip	1	medium	Core IP at or near expiry; commercial relevance fading.	CL · 2026-04-25
dealability	1	high	Multiple commercial transfers and limited uptake make this an unattractive platform-licensing story.	CL · 2026-04-25
availability	1	high	Probuphine commercial product was discontinued post-2020. Titan Pharmaceuticals retains the ProNeura implant platform but commercial activity has wound down to maintenance. Effectively closed.	CL · 2026-04-27

Analytical view
Tracked as competitive context and as a cautionary tale — Probuphine illustrates that LAI duration alone does not win markets; site-of-care workflow and prescriber preference matter more. The 6-month duration was insufficient compensation for surgical insertion friction. Strategic read-across to any prospective implant LAI in indications where injectable alternatives exist.

Sandostatin LAR

1.90

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	Long commercial track record (1998+) for peptide LAI; reference for somatostatin analog delivery.	CL · 2026-04-25
ip	1	high	Off-patent.	CL · 2026-04-25
dealability	1	high	Internal Novartis asset.	CL · 2026-04-25
availability	1	high	Novartis-internal mature franchise post-Recordati Signifor divestiture. No platform-licensing posture for external partners.	CL · 2026-04-27

Analytical view
Reference product for peptide LAI commercial economics in endocrine oncology. Strategic read-across — Camurus CAM2029 (octreotide via FluidCrystal) directly challenges this franchise; Sandostatin LAR's current sales trajectory under generic and biosimilar pressure provides the price ceiling for any new octreotide LAI entrant.

Signifor LAR

1.80

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	3	high	Approved product but narrow indication scope; mechanism conventional PLGA microsphere.	CL · 2026-04-25
ip	2	medium	Patent runway short; commercial moat eroding.	CL · 2026-04-25
dealability	1	high	Mature asset within rare-disease specialist company; not externally licensable.	CL · 2026-04-25
availability	1	high	Recordati-internal post-2019 acquisition from Novartis. Rare-disease commercial focus does not include external platform licensing. Pasireotide indication scope encumbered.	CL · 2026-04-27

Analytical view
Niche endocrine LAI tracked for competitive context. Strategic relevance is as a precedent for rare-disease LAI economics — Recordati's acquisition from Novartis demonstrates that mature LAI franchises can be transferred between strategics at meaningful multiples even with patent expiry approaching.

Somatuline Autogel

2.10

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	Novel self-assembling nanotube mechanism distinct from polymer LAI; demonstrated commercial success across two indications; convenient administration profile.	CL · 2026-04-25
ip	2	medium	Core IP nearing or at expiry; product-specific extensions provide some additional runway.	CL · 2026-04-25
dealability	1	high	Internal Ipsen flagship asset; not externally licensable.	CL · 2026-04-25
availability	1	high	Ipsen-internal franchise; founder-family majority control restricts external platform deals. Self-assembling peptide mechanism is uniquely Ipsen's manufacturing know-how. Closed.	CL · 2026-04-27

Analytical view
Reference peptide LAI for somatostatin analog category with novel self-assembly mechanism. Tracked for competitive context against Sandostatin LAR and Camurus CAM2029. Unusual mechanism makes this a technically distinctive entry that warrants ongoing attention even as core IP runs off.

SpectruM

3.75

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	Two approved formulations (monthly and 6-month) of the same molecule demonstrate platform flexibility on duration; commercial validation in major markets.	CL · 2026-04-25
ip	4	medium	Reasonable patent runway with active continuation strategy; specific expiry verification needed.	CL · 2026-04-25
dealability	3	medium	Single notable partnership (Accord) is mid-tier; no Big Pharma deals to date; commercialization-focused strategy.	CL · 2026-04-25
availability	4	medium	Foresee Pharmaceuticals' commercial model is explicitly platform-licensing-driven (Camcevi via Accord ex-US, Intas US, GenSci China). LHRH oncology scope is encumbered globally but other therapeutic areas remain open subject to Foresee BD bandwidth.	CL · 2026-04-27

Analytical view
Asian-domiciled (Taiwan) platform commercializing in Western markets via partner — interesting model but not a platform commanding licensing premium. Camcevi competes with Eligard, Lupron Depot, and Trelstar in mature LHRH category. Investment thesis is product-economics-driven, not platform-driven.

Trelstar

2.40

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	Multiple duration formats demonstrate platform flexibility; decades of commercial use; reliable PK characterization.	CL · 2026-04-25
ip	1	high	Off-patent.	CL · 2026-04-25
dealability	2	high	Mature product; commercial transfers continue (e.g., Verity for US) but platform-licensing not active.	CL · 2026-04-25
availability	2	medium	Debiopharm-Ipsen co-managed mature franchise (Decapeptyl/Trelstar). Triptorelin oncology scope commercially saturated; private-family ownership at Debiopharm and founder-family control at Ipsen restrict external platform-level deals.	CL · 2026-04-27

Analytical view
Tracked for competitive context in LHRH LAI category. Decapeptyl/Trelstar's European market share is durable despite IP expiry — the LHRH LAI category has demonstrated strong post-LOE persistence due to prescriber inertia and manufacturing barriers. Read-across for new entrants: take share will require structural advantage (duration, tolerability, or pricing), not just regulatory approval.

Zoladex

1.90

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	Solid-rod implant approach long established and reliable for goserelin; alternative duration options demonstrate flexibility within the format.	CL · 2026-04-25
ip	1	high	Off-patent.	CL · 2026-04-25
dealability	1	high	Mature product; no licensing optionality beyond region-specific commercial transfers (already executed).	CL · 2026-04-25
availability	1	high	AstraZeneca-internal globally; US rights with TerSera. Off-patent commodity at this point. No platform-licensing posture.	CL · 2026-04-27

Analytical view
Reference solid-implant platform for peptide LAI. Tracked for indication-fit context in the platform H2H matrix. Competitive context for any new solid- rod implant entrant — Zoladex's commercial entrenchment in oncology hormonal therapy is durable despite IP expiry.

iDose

2.70

Dimension	Score	Confidence	Rationale	Scorer · Date
tech	4	high	One approved product with up to 36-month demonstrated efficacy in Phase 3; novel non-bioerodible titanium device approach.	CL · 2026-04-25
ip	5	medium	Strong patent estate with continuations; novel device-based mechanism creates distinct IP space from polymer implants.	CL · 2026-04-25
dealability	1	high	Glaukos commercializes iDose internally; no external licensing opportunity.	CL · 2026-04-25
availability	1	high	Glaukos-internal commercial asset (iDose TR launched 2024); no platform-licensing signal. Closed for external partners.	CL · 2026-04-27

Analytical view
Internal Glaukos asset, not externally investable as platform. Strategic significance for us is as a benchmark — iDose's longer duration pressures Allergan's Durysta and sets a higher bar for any new ophthalmic LAI platform. Watch commercial uptake post-launch as a leading indicator for prescriber/patient acceptance of multi-year ocular implants.

Partner Availability

For pharma BD scouting. ✓ = indication open for partnering. 🔒 = encumbered by an active exclusive deal. Color follows the indication-fit score.

Platform	Posture	Psych	Addiction	HIV	Oncology	Endocrine	Ophtho	Pain	Metabolic
Atrigel	—	2 ✓	5 ✓	—	5 ✓	3 ✓	—	—	—
BEPO	Selective	5 🔒	3 ✓	3 ✓	3 🔒	—	4 🔒	—	—
Biochronomer	—	—	—	—	3 ✓	—	—	4 ✓	—
Chroniject	—	—	—	—	—	—	—	—	—
DepoFoam	—	—	—	—	1 ✓	—	—	4 ✓	—
Durasert	Selective	—	—	—	—	—	5 🔒	—	—
FluidCrystal	Selective	3 ✓	5 🔒	—	3 ✓	4 🔒	—	—	5 🔒
ISM	—	4 ✓	—	—	3 ✓	3 ✓	—	—	—
Lupron Depot	—	—	—	—	5 ✓	5 ✓	—	—	—
MariTide platform (Amgen)	—	—	—	—	—	—	—	—	4 ✓
Medisorb	Selective	5 ✓	4 ✓	—	—	3 🔒	—	—	—
Medusa	—	—	—	—	—	—	—	—	3 ✓
Metsera depot platform	—	—	—	—	—	—	—	—	4 ✓
NanoCrystal	Selective	5 ✓	—	5 🔒	—	—	—	—	—
NanoZolid	—	—	—	—	3 ✓	—	—	—	—
Novadur	—	—	—	—	—	—	5 ✓	—	—
Oil decanoate	—	4 ✓	—	—	4 ✓	5 ✓	—	—	—
PDS (Susvimo)	—	—	—	—	—	—	5 ✓	—	—
Perseris	—	3 ✓	—	—	—	—	—	—	—
PolyActiva	—	—	—	—	—	—	3 ✓	—	—
Probuphine	—	—	2 ✓	—	—	—	—	—	—
Sandostatin LAR	—	—	—	—	4 ✓	5 ✓	—	—	—
Signifor LAR	Selective	—	—	—	3 ✓	4 🔒	—	—	—
Somatuline Autogel	—	—	—	—	5 ✓	5 ✓	—	—	—
SpectruM	Selective	—	—	—	4 🔒	—	—	—	—
Trelstar	—	—	—	—	5 ✓	4 ✓	—	—	—
Zoladex	—	—	—	—	5 ✓	4 ✓	—	—	—
iDose	—	—	—	—	—	—	5 ✓	—	—

Platform Technical Fit

Label-derived screening attributes for pharma scientist BD diligence.

Platform	Mechanism	Duration	Payloads	Vol (mL)	Needle	Cold chain	Site	Capacity
Atrigel	In-situ depot	30d – 6mo	Small molecule, Peptide	0.25–0.5	19G	Yes	SC	Moderate
BEPO	In-situ depot	7d – 3mo	Small molecule, Peptide	0.3–2.0	21G	No	SC, IM	Moderate
Biochronomer	In-situ depot	3–7d	Small molecule	0.5–30.0	23-25G	Yes	Local infiltration, SC	Moderate
Chroniject	Microsphere	7d – 12mo	Small molecule, Peptide, Protein	0.5–2.0	21G	Yes	IM, SC	Moderate
DepoFoam	Liposome	3–4d	Small molecule	0.5–30.0	25G	Yes	Local infiltration, Intra-articular	Moderate
Durasert	Implant	180d – 36mo	Small molecule	—	25G inserter	No	Intravitreal	Moderate
FluidCrystal	In-situ depot	7d – 6mo	Small molecule, Peptide	0.16–1.5	23G	No	SC, IM	Moderate
ISM	In-situ depot	28d – 3mo	Small molecule, Peptide	1.0–1.5	21G	No	IM	Ample
Lupron Depot	Microsphere	28d – 6mo	Peptide	1.0–2.0	22G	No	IM, SC	Ample
MariTide platform (Amgen)	Other	28d – 3mo	Peptide, Biologic	—	—	Yes	SC	—
Medisorb	Microsphere	14–28d	Small molecule, Peptide	0.5–3.4	20G	Yes	IM	Ample
Medusa	Drug conjugate	3–30d	Peptide, Protein	0.5–2.0	27G	Yes	SC	Tight
Metsera depot platform	Other	28d – 3mo	Peptide	—	—	Yes	SC	—
NanoCrystal	Nanocrystal	28d – 6mo	Small molecule	0.875–1.5	22G	No	IM	Ample
NanoZolid	In-situ depot	90d – 6mo	Small molecule, Peptide, Protein	1.0–5.0	22G	Yes	Intratumoral, Intra-articular	Tight
Novadur	Implant	90d – 6mo	Small molecule	—	28G inserter	No	Intracameral	Ample
Oil decanoate	Oil depot	14–28d	Small molecule	1.0–3.0	21G	No	IM	Ample
PDS (Susvimo)	Implant	120d – 6mo	Biologic	0.05	34G refill needle	Yes	Intravitreal device	Moderate
Perseris	In-situ depot	30–30d	Small molecule	0.6	18G	No	SC	Tight
PolyActiva	Implant	180d – 12mo	Small molecule	—	27G inserter	No	Intracameral	Tight
Probuphine	Implant	180d – 6mo	Small molecule	—	applicator (incision-based insertion)	No	SC implant	Tight
Sandostatin LAR	Microsphere	28–28d	Peptide	2.5	19G	Yes	IM	Ample
Signifor LAR	Microsphere	28–28d	Peptide	2.0	20G	Yes	IM	Ample
Somatuline Autogel	In-situ depot	28–56d	Peptide	0.5	1.2 x 60 mm pre-filled syringe	Yes	SC	Moderate
SpectruM	In-situ depot	30d – 6mo	Small molecule, Peptide	0.25–0.375	18G	Yes	SC	Moderate
Trelstar	Microsphere	28d – 6mo	Peptide	2.0	21G	No	IM	Ample
Zoladex	Implant	28d – 3mo	Peptide	—	14-16G implanter	No	SC implant	Ample
iDose	Implant	90d – 36mo	Small molecule	—	27G inserter	No	Intracameral	Moderate

Encumbrance Log

Active exclusive deals locking indication scope. BD scouts treat these as unavailable.

Platform	Indication	Locked by	Since	Molecules	Territory
BEPO	cns_neuro	AbbVie 2024_abbvie_medincell	2024-04-16	undisclosed	worldwide
BEPO	oncology	AbbVie 2024_abbvie_medincell	2024-04-16	undisclosed	worldwide
BEPO	ophthalmology	AbbVie 2024_abbvie_medincell	2024-04-16	undisclosed	worldwide
BEPO	other	AbbVie 2024_abbvie_medincell	2024-04-16	undisclosed	worldwide
BEPO	psych	Teva 2013_teva_medincell	2013-11-01	risperidone, olanzapine, third CNS LAI	worldwide
Durasert	ophthalmology	Alimera Sciences 2008_alimera_eyepoint_iluvien	2008-02-12	fluocinolone acetonide	Worldwide
FluidCrystal	addiction	Braeburn 2014_braeburn_camurus	2014-11-20	buprenorphine, buprenorphine combinations	North America (with Asia options)
FluidCrystal	endocrine	Eli Lilly and Company 2025_lilly_camurus_incretins	2025-06-03	GIP/GLP-1 agonists, GIP/glucagon/GLP-1 agonists, amylin receptor agonists	worldwide
FluidCrystal	metabolic	Eli Lilly and Company 2025_lilly_camurus_incretins	2025-06-03	GIP/GLP-1 agonists, GIP/glucagon/GLP-1 agonists, amylin receptor agonists	worldwide
FluidCrystal	pain	Braeburn 2014_braeburn_camurus	2014-11-20	buprenorphine, buprenorphine combinations	North America (with Asia options)
FluidCrystal	pain	Braeburn 2016_braeburn_camurus_cam2058_amendment	2016-10-24	buprenorphine-granisetron	North America
Medisorb	endocrine	AstraZeneca / later Eli Lilly 2014_az_alkermes_bydureon	2014-02-01	exenatide	Worldwide (with regional commercial transitions)
NanoCrystal	hiv	ViiV Healthcare 2016_viiv_janssen_cabenuva	2016-01-07	rilpivirine	Worldwide
Signifor LAR	endocrine	Recordati Rare Diseases 2019_recordati_novartis_signifor	2019-07-12	pasireotide	Worldwide
SpectruM	oncology	Accord Healthcare 2019_accord_foresee_camcevi	2019-02-11	leuprolide mesylate	Global excl. US, mainland China, Japan, Taiwan, Israel, Turkey, certain Middle East
SpectruM	oncology	Intas Pharmaceuticals (Accord BioPharma US) 2021_intas_foresee_camcevi	2021-03-04	leuprolide mesylate	United States

Asset thesis tracker

Click any column header to sort. Click again to reverse.

Asset	Platform	Owner	Indication	Phase	Sales	Next catalyst	Composite
AbbVie BEPO Program 1 (awaiting disclosure) undisclosed	BEPO	MedinCell / AbbVie	Other	preclinical	—	2026-Q4	2.85
Apretude cabotegravir	NanoCrystal	ViiV Healthcare	HIV	approved	—	—	4.65
Brixadi buprenorphine	FluidCrystal	Camurus / Braeburn	Addiction	approved	$20M (2024)	—	4.30
Buvidal buprenorphine	FluidCrystal	Camurus	Addiction	approved	$157M (2024)	—	4.50
CAM2029 (Oclaiz) octreotide	FluidCrystal	Camurus	Endocrine	phase_3	—	2026-Q2	3.90
CAM2032 setmelanotide	FluidCrystal	Camurus / Rhythm Pharmaceuticals	Endocrine	phase_2	—	2026-Q4	3.30
Cabenuva cabotegravir + rilpivirine	NanoCrystal	ViiV Healthcare	HIV	approved	—	—	4.85
Durysta bimatoprost	Novadur	AbbVie / Allergan	Ophtho	approved	—	—	3.25
EYP-1901 (DURAVYU) vorolanib	Durasert	EyePoint Pharmaceuticals	Ophtho	phase_3	—	2026-Q4	3.55
Eligard leuprolide acetate	Atrigel	Tolmar	Oncology	approved	—	—	3.95
Exparel bupivacaine liposomal	DepoFoam	Pacira BioSciences	Pain	approved	$540M (2024)	—	3.05
Invega Hafyera paliperidone palmitate (6-monthly)	NanoCrystal	Janssen (Johnson & Johnson)	Psych	approved	—	—	3.75
Invega Sustenna paliperidone palmitate	NanoCrystal	Janssen (Johnson & Johnson)	Psych	approved	$4500M (2024)	—	3.90
Lupron Depot leuprolide acetate	Lupron Depot	AbbVie / Takeda	Oncology	approved	$800M (2024)	—	3.60
MET-097 undisclosed long-acting GLP-1	Metsera depot platform	Metsera (Pfizer-acquired)	Metabolic	phase_2	—	2026-Q3	3.85
MariTide maridebart cafraglutide (AMG 133)	MariTide platform (Amgen)	Amgen	Metabolic	phase_3	—	2026-Q4	2.75
PA5108 latanoprost	PolyActiva	PolyActiva Pty Ltd	Ophtho	phase_2	—	2026-Q3	2.50
Risperdal Consta risperidone	Medisorb	Janssen (Johnson & Johnson)	Psych	approved	—	—	3.60
Risvan risperidone	ISM	Rovi	Psych	approved	—	—	3.45
Sandostatin LAR octreotide acetate	Sandostatin LAR	Novartis	Endocrine	approved	—	—	3.40
Somatuline Depot lanreotide	Somatuline Autogel	Ipsen	Endocrine	approved	$1100M (2024)	—	3.55
Sublocade buprenorphine	Atrigel	Indivior	Addiction	approved	—	—	4.10
Susvimo ranibizumab (via PDS)	PDS (Susvimo)	Genentech (Roche)	Ophtho	approved	—	—	3.40
TEV-749 (mdc-TJK) olanzapine	BEPO	MedinCell / Teva	Psych	phase_3	—	2026-Q4	4.05
UZEDY risperidone	BEPO	MedinCell / Teva	Psych	approved	$191M (2025)	2026-Q4	4.65
Vivitrol naltrexone	Medisorb	Alkermes	Addiction	approved	$410M (2024)	—	3.45
Zynrelef bupivacaine + meloxicam	Biochronomer	Heron Therapeutics	Pain	approved	$35M (2024)	—	3.40
iDose TR travoprost	iDose	Glaukos Corporation	Ophtho	approved	$50M (2024)	—	3.70

Target Screener

Public LAI-platform companies sized by market cap. M&A scouting view.

Company	Ticker	HQ	Mkt cap	Cash	Debt	Platforms
Eli Lilly and Company	LLY	US	$750,000M	$4,000M	$28,000M	fluidcrystal, medisorb
Johnson & Johnson (Janssen Pharmaceutical)	JNJ	US	$380,000M	$25,000M	$30,000M	nanocrystal, medisorb
AbbVie Inc.	ABBV	US	$320,000M	$12,000M	$60,000M	bepo, lupron_depot, novadur
F. Hoffmann-La Roche AG (Roche / Genentech)	ROG	CH	$280,000M	$6,000M	$35,000M	pds
AstraZeneca PLC	AZN	GB	$220,000M	$7,000M	$28,000M	zoladex_implant
Novartis AG	NVS	CH	$220,000M	$12,000M	$25,000M	sandostatin_lar_platform, signifor_lar
Amgen Inc.	AMGN	US	$165,000M	$8,000M	$60,000M	maritide
Pfizer Inc.	PFE	US	$160,000M	$12,000M	$60,000M	metsera_lai
GSK plc	GSK	GB	$75,000M	$5,000M	$22,000M	nanocrystal
Teva Pharmaceutical Industries Ltd.	TEVA	IL	$22,000M	$3,000M	$17,000M	bepo
Ipsen S.A.	IPN	FR	$11,000M	$800M	$1,800M	somatuline_autogel
Recordati S.p.A.	REC	IT	$11,000M	$200M	$1,300M	signifor_lar_platform
Alkermes plc	ALKS	IE	$5,500M	$800M	$300M	medisorb, nanocrystal
Camurus AB	CAMX	SE	$4,500M	$250M	—	fluidcrystal
Glaukos Corporation	GKOS	US	$4,500M	$250M	$280M	idose
Laboratorios Farmacéuticos Rovi, S.A.	ROVI	ES	$4,000M	$250M	$200M	ism
Indivior PLC	INDV	GB	$1,800M	$500M	$250M	atrigel, perseris
Pacira BioSciences, Inc.	PCRX	US	$1,100M	$350M	$400M	depofoam
EyePoint Pharmaceuticals, Inc.	EYPT	US	$600M	$280M	$50M	durasert
Heron Therapeutics, Inc.	HRTX	US	$250M	$60M	$120M	biochronomer
MedinCell SA	MEDCL	FR	$250M	$50M	—	bepo
Foresee Pharmaceuticals Co., Ltd.	6576	TW	$130M	—	—	spectrum
Adocia SA	ADOC	FR	$50M	$15M	—	medusa
LIDDS AB	LIDDS	SE	$10M	—	—	nanozolid
Titan Pharmaceuticals, Inc.	TTNP	US	$5M	—	—	probuphine

Deal log

Click any column header to sort. Click again to reverse.

Date	Counterparties	Platform	Type	Upfront	Milestones	Territory	Disclosure
2025-09-22	Metsera, Inc. × Pfizer Inc.	Metsera depot platform	m_and_a	$4900M	$2300M	Worldwide	partial
2025-06-03	Camurus × Eli Lilly and Company cardiometabolic incretins	FluidCrystal	licensing	undisc.	$870M	Worldwide	partial
2024-10-01	EyePoint Pharmaceuticals × Ono Pharmaceutical Co., Ltd. EYP-1901 (DURAVYU)	Durasert	licensing	$25M	$130M	Japan, South Korea, Taiwan, certain other Asian territories	partial
2024-07-09	Indivior × (discontinued — no buyer) discontinuation	Perseris	licensing	undisc.	undisc.	United States	full
2024-05-01	GlycoMimetics, Inc. × Pacira BioSciences, Inc.	DepoFoam	m_and_a	undisc.	undisc.	Worldwide	minimal
2024-04-16	MedinCell × AbbVie BEPO (multi-program)	BEPO	licensing	$35M	$1900M	Worldwide	partial
2024-01-01	PolyActiva Pty Ltd × undisclosed pharma counterparty	PolyActiva	licensing	undisc.	undisc.	undisclosed	minimal
2023-11-13	Teva Pharmaceuticals International GmbH × Royalty Pharma olanzapine LAI funding	BEPO	royalty_purchase	$100M	$125M	Worldwide	full
2023-10-01	Astellas Pharma Inc. × EyePoint Pharmaceuticals	Durasert	licensing	undisc.	undisc.	Worldwide	minimal
2021-03-04	Foresee Pharmaceuticals × Intas Pharmaceuticals (Accord BioPharma US) Camcevi	SpectruM	licensing	$10M	$207M	United States	partial
2019-07-12	Novartis × Recordati Rare Diseases Signifor + osilodrostat	Signifor LAR	m_and_a	$390M	undisc.	Worldwide	partial
2019-02-11	Foresee Pharmaceuticals × Accord Healthcare Camcevi	SpectruM	licensing	undisc.	$86M	Global excl. US, mainland China, Japan, Taiwan, Israel, Turkey, certain Middle East	partial
2018-12-31	Camurus × Braeburn Inc. Brixadi	FluidCrystal	licensing	undisc.	undisc.	North America (with Asia options)	minimal
2018-12-01	Tolmar (former owners — undisclosed PE) × The Carlyle Group LP	Atrigel	m_and_a	undisc.	undisc.	Worldwide	minimal
2016-10-24	Camurus × Braeburn amendment	FluidCrystal	licensing	undisc.	undisc.	North America (with Asia options)	minimal
2016-01-07	Janssen (Johnson & Johnson) × ViiV Healthcare Cabenuva	NanoCrystal	licensing	undisc.	undisc.	Worldwide	minimal
2014-11-20	Camurus × Braeburn Brixadi	FluidCrystal	licensing	$20M	$131M	North America (with options for Japan, Korea, Taiwan, China)	full
2014-02-01	Alkermes × AstraZeneca / later Eli Lilly Bydureon	Medisorb	royalty_purchase	undisc.	undisc.	Worldwide (with regional commercial transitions)	full
2013-11-01	MedinCell × Teva UZEDY	BEPO	licensing	undisc.	$366M	Worldwide	partial
2008-02-12	EyePoint Pharmaceuticals × Alimera Sciences Iluvien	Durasert	licensing	undisc.	undisc.	Worldwide	partial

Clinical Trials Coverage

166 trials indexed; 53 active or pre-readout; 87 Phase 3. Sourced from ClinicalTrials.gov via scripts/scrape_clinicaltrials.py.

Asset	Platform	Total trials	Active	Phase 3
MariTide	MariTide platform (Amgen)	15	11	7
Somatuline Depot	Somatuline Autogel	13	0	9
Sublocade	Atrigel	11	1	2
Cabenuva	NanoCrystal	10	5	5
Susvimo	PDS (Susvimo)	10	2	4
Vivitrol	Medisorb	10	0	9
Zynrelef	Biochronomer	10	2	2
Sandostatin LAR	Sandostatin LAR	9	3	6
Apretude	NanoCrystal	8	5	4
Invega Hafyera	NanoCrystal	8	0	5
Invega Sustenna	NanoCrystal	8	0	4
MET-097	Metsera depot platform	8	6	2
iDose TR	iDose	8	7	4
CAM2029 (Oclaiz)	FluidCrystal	7	3	6
EYP-1901 (DURAVYU)	Durasert	7	4	4
Exparel	DepoFoam	6	0	2
Eligard	Atrigel	4	2	4
PA5108	PolyActiva	3	1	0
UZEDY	BEPO	3	0	3
Brixadi	FluidCrystal	2	0	2
TEV-749 (mdc-TJK)	BEPO	2	0	2
AbbVie BEPO Program 1 (awaiting disclosure)	BEPO	1	1	0
Buvidal	FluidCrystal	1	0	1
CAM2032	FluidCrystal	1	0	0
Durysta	Novadur	1	0	0

IP Coverage

108 patent records indexed from FDA Orange Book and curated filings. Sourced via scripts/scrape_orange_book.py.

Platform	Patents	Earliest expiry	Latest expiry
DepoFoam	21	2041-01-22	2044-07-02
NanoCrystal	21	2019-11-20	2041-11-24
Atrigel	18	2008-10-03	2041-12-22
FluidCrystal	12	2025-06-03	2037-05-05
Durasert	8	2027-08-12	2039-06-23
Novadur	7	2026-12-19	2034-10-31
BEPO	5	2031-12-23	2038-06-13
ISM	5	2032-04-10	2032-04-10
Signifor LAR	3	2026-10-25	2028-05-23
Lupron Depot	2	2028-03-22	2031-02-05
MariTide platform (Amgen)	2	2038-02-04	2043-11-07
Medisorb	1	2029-10-15	2029-10-15
Metsera depot platform	1	2037-04-15	2037-04-15
PDS (Susvimo)	1	2035-06-04	2035-06-04
Somatuline Autogel	1	2022-04-25	2022-04-25